Navigation Links
Oncolytics Biotech Inc. Announces 2007 Third Quarter Results
Date:10/30/2007

CALGARY, Oct. 30 /PRNewswire-FirstCall/ - Oncolytics Biotech Inc. ("Oncolytics") (TSX:ONC, NASDAQ:ONCY) today announced its financial results and highlights for the three and nine-month periods ended September 30, 2007.

Third Quarter Highlights

- Announced positive interim results from a U.K. Phase Ia/1b

combination REOLYSIN(R) and radiation trial for patients with

advanced cancers - including partial and remote responses in patients

with a variety of advanced cancers;

- Commenced patient enrolment in a multi-centre, combination

REOLYSIN(R) and docetaxel (Taxotere(R)) systemic administration trial

in the U.K.;

- In October, received approval from the U.K. regulatory authorities to

begin a combination REOLYSIN(R) and cyclophosphamide trial for

patients with advanced cancers;

- Secured two additional U.S. patents, for a total of more than 150

issued patents worldwide; and,

- Presented preclinical work at the National Cancer Research Institute

Conference in Birmingham, U.K. demonstrating for the first time how

reovirus-infected melanoma cells stimulate dendritic cells to prime

the immune system against cancer cells.

"With positive results being reported from our clinical trial program in the U.K. and the U.S., seven trials actively enrolling, an additional combination trial approved to begin and an expanding intellectual property portfolio supporting our technology, Oncolytics is looking forward to making substantial progress through the balance of 2007 and 2008," said Dr. Brad Thompson, President and CEO of Oncolytics.

Oncolytics Biotech Inc.

BALANCE SHEETS

(unaudited)

As at,

September 30, December 31,


'/>"/>

SOURCE Oncolytics Biotech Inc.
Copyright©2007 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29

Related biology technology :

1. The state of global biotech: An Ernst & Young perspective
2. Olympics of biotechnology has international flavor
3. Biotech officials praise focus of new venture fund
4. Getting noticed in Genetown: Wisconsin biotech on display
5. Madison biotech NimbleGen files for IPO; one of states best-funded firms
6. Wisconsin biotech firm receives $107K NIH grant
7. Biotech executive books a career flight thats closer to home
8. Manufacturing partnership will move into biotech and biomedical spaces
9. Wisconsin wont get Georgia biotech without a fight
10. The 10 biggest events shaping biotech in 2006
11. Gala Biotech among companies sold for $3.3 billion
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/25/2014)... October 24, 2014 Today, Nerium International, ... the winners of its “Reflect Your Youth” contest, an ... only seen a difference in their skin since using ... new outlook on life as a result of their ... as an effort by Nerium International to inspire conversations ...
(Date:10/25/2014)... Durham, NC (PRWEB) October 24, 2014 ... appears to overcome several pitfalls of current skin grafting ... scarring and produces hair. The method, outlined in the ... a breakthrough for treating deep skin injuries that result ... skin injury completely destroys the skin’s regenerative elements. These ...
(Date:10/25/2014)... October 24, 2014 Oramed Pharmaceuticals ... company focused on the development of oral drug delivery ... Kidron will present at FireRock Capital,s Micro-Cap Conference. ... Micro-Cap Conference ,Date: Tuesday, October 28, 2014 ,Time: 9:15am ... New York City , About ...
(Date:10/25/2014)... Oct. 24, 2014  RegeneRx Biopharmaceuticals, Inc. (OTCBB: RGRX) ("the ... the Fourth International Symposium on Thymosins in Health and ... "When thymosin beta 4 (TB4) linked with ... peritoneal cavity in a rodent model of stroke, it ... brain parenchyma (the functional tissue of the brain).   The ...
Breaking Biology Technology:Nerium International™ Inspires Conversation About the Journey of Aging with “Reflect Your Youth” Contest 2New engineering method shows promise for faster healing, more cosmetically appealing skin grafts 2New engineering method shows promise for faster healing, more cosmetically appealing skin grafts 3Oramed to Present at the FireRock Annual Micro-Cap Conference 2Oramed to Present at the FireRock Annual Micro-Cap Conference 3Researchers Report Thymosin Beta 4 Crosses Blood-Brain Barrier In Animal Stroke Model 2
... Wash., June 16, 2011 SCOLR Pharma, Inc. (OTC: ... of $1 million principal amount of its 8% Senior ... initial closing of its private offering of up to ... offer additional Debentures, up to the aggregate maximum of ...
... KNDL ), a leading, global full-service ... senior clinical development experts will present on important ... 47th Annual Meeting, June 19-23, 2011, in Chicago. ... benefits of hybrid monitoring; finding an economic balance ...
... 2011 MacuCLEAR, Inc., a specialty clinical stage pharmaceutical ... vascular disorders of the eye, announced today that Philip ... OneMedForum New York 2011 on Thursday, June 23, 2011 ... New York City.   OneMedForum will focus ...
Cached Biology Technology:SCOLR Pharma, Inc. Announces Initial Closing of Private Placement 2SCOLR Pharma, Inc. Announces Initial Closing of Private Placement 3Kendle Experts to Address Key Industry Issues at Drug Information Association 47th Annual Meeting 2Kendle Experts to Address Key Industry Issues at Drug Information Association 47th Annual Meeting 3MacuCLEAR, Inc. to Present at OneMedForum New York 2011 and at the 2011 BIO Business Forum During the Annual BIO International Convention in Washington, D.C. 2
(Date:10/19/2014)... Improving household electricity access in India over the ... nation,s total carbon emissions growth during that time, ... journal Nature Climate Change ., "Energy access ... all aspects of life, including education, communication, and ... the study. , While increased energy access is ...
(Date:10/17/2014)... Rockville, MD – Accurate knowledge regarding Ebola is critical ... current risk of hazardous global outbreak and epidemic. The ... has launched a special issue, Ebola Virus and Public ... with necessary knowledge in this critical societal moment. ... Primer on Ebola for Clinicians . The primer was ...
(Date:10/16/2014)... Cancer constantly wages war on the human body. ... a stalemate. In pancreatic cancer, this stalemate—known as ... becoming aggressively malignant, a phenomena that is poorly ... in the laboratory of Salvatore Torquato, a Professor ... the conditions surrounding tumor dormancy and the switch ...
Breaking Biology News(10 mins):Improved electricity access has little impact on climate change 2Modeling tumor dormancy 2
... found a way of stimulating the immune systems ... the devastating plaques,that are characteristic of Alzheimer's disease.,For ... a,protein-based vaccine to slow the progression of the ... created a gene-based,vaccine aimed at stimulating the immune ...
... cells',responsible for hearing and balance. Traditionally viewed as ... for the normal development,of nerve cells responsible for ... research. The study is reported in the January ... scientists at the University,of Washington.,"Using zebrafish as a ...
... essential for 'hair cells',responsible for hearing and balance. ... may be essential for the normal development,of nerve ... new,University of Utah research. The study is reported ... is co-authored by scientists at the University,of Washington.,"Using ...
Cached Biology News:Gene vaccine for Alzheimer's disease shows promising results 2GenMAPP 2.0 released 2Harmful Bacterium Commonly Found in Poultry May Survive Refrigeration and Frozen Storage Combined 2
Mouse monoclonal antibody raised against a partial recombinant ZNF155. NCBI Entrez Gene ID = ZNF155...
... macroporous polystyrene beads for hydrophobic interaction chromatography. ... adsorbing organics of molecular weight less than ... useful for the adsorption of nonpolar substances ... removal of detergents such as Triton X-100 ...
... : Fusion protein corresponding to ... human Mi-2 Formulation: 0.7M Tris-glycine, ... sodium azide, containing 30% glycerol ... immunoblot on Hela nuclear extract ...
... Phospho-Specific(Thr 222 ) ... 10 mM sodium HEPES, 100 ... 7.5. Recognizes the ~47 kDa ... (MAPKAPK-2) protein phosphorylated at Thr ...
Biology Products: